Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines
Open Access
Abstract
Human tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies.Keywords
This publication has 372 references indexed in Scilit:
- A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosisKidney International, 2011
- Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected databaseEuropean Journal of Cancer, 2009
- TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEuropean Journal of Immunology, 2009
- Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancerGynecologic Oncology, 2009
- Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung NeoplasmsThe Annals of Thoracic Surgery, 2009
- Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127–35Clinical Immunology, 2008
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinomaEuropean Journal of Cancer, 1994
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Lymphocyte infiltrates as a prognostic variable in female breast cancerEuropean Journal of Cancer, 1992